Paracetamol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Analgesic and Antipyretic
Subclass
Non-opioid Analgesic (Para-aminophenol Derivative)
Speciality
Pain medicine
Schedule (India)
Non-scheduled (monotherapy in standard strengths) / Schedule H (in certain combinations)
Routes
Oral, Intravenous (IV), Rectal
Formulations
- Tablets: 325 mg, 500 mg, 650 mg, 1000 mg
- Dispersible/Soluble tablets: 125 mg, 250 mg, 500 mg
- Oral suspension/Syrup: 120 mg/5 mL, 125 mg/5 mL, 250 mg/5 mL
- Paediatric drops: 100 mg/mL, 150 mg/mL
- Intravenous infusion: 10 mg/mL (100 mL vial = 1000 mg)
- Suppositories (Paediatric): 80 mg, 125 mg, 170 mg, 250 mg, 500 mg
Adult indications
NDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Fever (Antipyretic)
Adults — Oral:
| Parameter | Dose |
|---|---|
|
Starting dose
|
500–1000 mg orally |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
500–1000 mg every 4–6 hours as needed |
|
Maximum dose
|
4000 mg/day (3000 mg/day in patients with hepatic risk factors) |
Clinical Notes:
- Maintain minimum 4-hour interval between doses
- Use lowest effective dose for shortest duration
- Efficacy for fever reduction similar to ibuprofen; onset within 30–60 minutes
- Duration of antipyretic effect: 4–6 hours
2. Mild to Moderate Pain (Headache, Musculoskeletal Pain, Dental Pain, Dysmenorrhoea)
Adults — Oral:
| Parameter | Dose |
|---|---|
|
Starting dose
|
500–1000 mg orally |
|
Titration
|
Not applicable for acute use |
|
Usual maintenance dose
|
500–1000 mg every 4–6 hours as needed |
|
Maximum dose
|
4000 mg/day |
Clinical Notes:
- First-line analgesic for mild to moderate pain
- Preferred over NSAIDs in patients with GI, renal, or cardiovascular risk factors
- May be combined with weak opioids (codeine, tramadol) for moderate pain — calculate total paracetamol from all sources
3. Postoperative Pain (Intravenous — Hospital Setting)
Adults — Intravenous:
| Parameter | Dose |
|---|---|
|
Starting dose
|
1000 mg IV infusion over 15 minutes |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
1000 mg IV every 4–6 hours |
|
Maximum dose
|
4000 mg/day |
For Adults <50 kg Body Weight:
| Parameter | Dose |
|---|---|
|
Starting dose
|
15 mg/kg IV (maximum 750 mg per dose) |
|
Usual maintenance dose
|
15 mg/kg every 4–6 hours |
|
Maximum dose
|
60 mg/kg/day (maximum 3000 mg/day) |
Clinical Notes:
- Use as part of multimodal analgesia to reduce opioid requirements
- IV route provides faster onset (5–10 minutes) compared to oral
- Reserve IV for patients unable to take oral medications
- Switch to oral formulation as soon as clinically feasible (cost consideration)
Secondary Indications – Adults (Off-label)
| Indication | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|
|
Osteoarthritis — Mild Pain (OFF-LABEL)
|
500–1000 mg orally three to four times daily; Maximum: 3000–4000 mg/day | Long-term as needed | Not required | Indian rheumatology practice; EULAR/ACR guidelines recommend as first-line before NSAIDs; limited efficacy in moderate-severe OA pain |
|
Migraine — Acute Treatment (Adjunct) (OFF-LABEL)
|
1000 mg orally at onset; may combine with caffeine or antiemetic; Maximum: single dose or repeat after 4–6 hours | Single attack; avoid chronic daily use | Not required | Indian Headache Society recommendations; RCTs show efficacy for mild-moderate migraine |
|
Tension-type Headache (OFF-LABEL)
|
500–1000 mg orally at onset | As needed; limit to <15 days/month | Not required | Cochrane review; first-line for episodic TTH |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Paracetamol is the preferred antipyretic and analgesic in children. Weight-based dosing is essential to avoid under- or overdosing.
Primary Indications: Fever and Mild to Moderate Pain
Oral Dosing (Syrup/Drops/Dispersible Tablets):
| Preterm neonates (<32 weeks) | 10–12 mg/kg | Every 8–12 hours | 30 mg/kg/day |
|---|---|---|---|
|
Term neonates (0–28 days)
|
10–15 mg/kg | Every 6–8 hours | 60 mg/kg/day |
|
1–3 months
|
10–15 mg/kg | Every 6–8 hours | 60 mg/kg/day |
|
3–12 months
|
10–15 mg/kg | Every 4–6 hours | 60 mg/kg/day |
|
1–5 years
|
10–15 mg/kg | Every 4–6 hours | 60 mg/kg/day (up to 75 mg/kg/day for short-term use under supervision) |
|
6–12 years
|
10–15 mg/kg | Every 4–6 hours | 60 mg/kg/day or 4000 mg/day (whichever is lower) |
|
>12 years
|
500–1000 mg | Every 4–6 hours | 4000 mg/day |
Rectal Dosing (Suppositories):
| Age | Dose | Frequency | Notes |
|---|---|---|---|
|
3 months–1 year
|
60–125 mg | Every 6–8 hours | Use when oral route not feasible |
|
1–5 years
|
125–250 mg | Every 4–6 hours | — |
|
6–12 years
|
250–500 mg | Every 4–6 hours | — |
Intravenous Dosing (Hospital Setting Only):
| Weight/Age | Dose | Frequency | Maximum Daily Dose |
|---|---|---|---|
|
Preterm neonates (≥32 weeks)
|
7.5 mg/kg | Every 8 hours | 22.5 mg/kg/day |
|
Term neonates to <10 kg
|
7.5 mg/kg | Every 4–6 hours | 30 mg/kg/day |
|
≥10 kg to <33 kg
|
15 mg/kg | Every 4–6 hours | 60 mg/kg/day |
|
33–50 kg
|
15 mg/kg | Every 4–6 hours | 60 mg/kg/day (max 3000 mg/day) |
|
>50 kg
|
1000 mg | Every 4–6 hours | 4000 mg/day |
Safety Monitoring:
- Always calculate dose based on actual body weight
- Ensure caregivers understand correct measuring technique for liquid formulations
- Calculate total paracetamol intake from all sources (including combination products)
- Monitor for hepatotoxicity signs if used for >3 days continuously
Clinical Notes:
- For infants <2 months with fever: specialist evaluation recommended before treatment (rule out serious bacterial infection)
- Paracetamol preferred over ibuprofen in children <6 months, those with dehydration, varicella, or dengue
- Alternating paracetamol and ibuprofen is not routinely recommended (risk of dosing errors)
Secondary Indications – Paediatrics (Off-label)
| Indication | Age | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|---|
|
Patent Ductus Arteriosus (PDA) Closure in Preterm Neonates (OFF-LABEL)
|
Preterm neonates | 15 mg/kg orally or IV every 6 hours | 3–7 days | Specialist only (Neonatologist) | Multiple RCTs (Hammerman et al., Ohlsson et al.); Indian NICU protocols; alternative when indomethacin/ibuprofen contraindicated or unavailable |
Age Restrictions:
- Infants <2 months: Use with caution; specialist evaluation recommended for underlying cause of fever
- Preterm neonates: Use only under neonatology supervision with appropriate dose adjustments
Renal Adjustments
| eGFR (mL/min/1.73 m²) | Recommendation |
|---|---|
|
≥50
|
No dose adjustment required |
|
10–50
|
No dose adjustment required; use standard doses |
|
<10
|
Extend dosing interval to every 6–8 hours; maximum 3000 mg/day |
|
Haemodialysis
|
Paracetamol is dialysable; dose post-dialysis if timing coincides; no supplemental dose usually required |
|
Peritoneal Dialysis
|
Use with caution; extend dosing interval |
Note: Paracetamol metabolites may accumulate in severe renal impairment; prefer oral over IV if possible.
Hepatic adjustment
Contraindications
- Known hypersensitivity to paracetamol or any excipients
- Severe hepatic impairment or active hepatic disease
- Acute hepatic failure
Cautions
- Chronic alcohol consumption (≥3 alcoholic drinks/day) — increased hepatotoxicity risk
- Malnutrition, anorexia nervosa, or prolonged fasting — depleted glutathione stores
- Chronic liver disease (mild to moderate)
- Severe renal impairment
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency (rare haemolysis reported at very high doses)
- Low body weight (<50 kg in adults) — adjust dosing accordingly
- Concurrent use with other paracetamol-containing products (FDCs, OTC cold/flu medicines) — risk of inadvertent overdose
- Prolonged use (>10 days without medical supervision)
- Dehydration
- Concurrent hepatotoxic medications (isoniazid, rifampicin, phenytoin, carbamazepine)
Pregnancy
| Parameter | Information |
|---|---|
|
Overall Safety
|
Considered safe in all trimesters; most widely used analgesic and antipyretic in pregnancy |
|
Risk
|
No confirmed teratogenic effects at therapeutic doses; some observational studies suggest possible association with ADHD/autism with prolonged high-dose use (unconfirmed, likely confounded) |
|
Preferred Alternatives
|
None — paracetamol is first-line for fever and mild-moderate pain in pregnancy |
|
When to Use
|
Use at lowest effective dose for shortest duration; avoid chronic daily use if possible |
|
Monitoring
|
Liver function in patients with pre-eclampsia, HELLP syndrome, or other hepatic conditions |
Lactation
| Parameter | Information |
|---|---|
|
Compatibility
|
Compatible with breastfeeding; considered safe |
|
Expected Drug Level in Milk
|
Very low (approximately 1–2% of maternal dose reaches infant) |
|
Risk to Infant
|
No significant adverse effects reported at therapeutic maternal doses |
|
Preferred Alternatives
|
None — paracetamol is preferred analgesic/antipyretic during breastfeeding |
|
Infant Monitoring
|
None routinely required; observe for rash (rare) with prolonged maternal use |
Elderly
| Parameter | Recommendation |
|---|---|
|
Starting dose
|
500 mg orally every 6–8 hours |
|
Titration
|
Not applicable |
|
Maximum recommended
|
3000 mg/day (reduced from standard adult maximum) |
|
Increased Risks
|
Hepatotoxicity (particularly if malnourished or with chronic alcohol use); accumulation if unrecognised renal or hepatic impairment |
|
Additional Precautions
|
Use lower doses in frail elderly or those with low body weight (<50 kg); assess for concurrent paracetamol intake from combination products; prefer paracetamol over NSAIDs due to superior GI and renal safety profile |
Major drug interactions
| Interacting Drug | Mechanism | Effect | Management |
|---|---|---|---|
|
Chronic Alcohol (>3 drinks/day)
|
CYP2E1 induction; glutathione depletion | Significantly increased hepatotoxicity risk even at therapeutic doses | Limit maximum daily dose to 2000 mg; counsel patients; avoid if possible |
|
Warfarin (high-dose paracetamol >2 g/day for >3 days)
|
Unknown mechanism; possible inhibition of vitamin K-dependent factors | Potentiation of anticoagulant effect; increased INR | Monitor INR closely; may need warfarin dose reduction; occasional/low-dose use unlikely to be significant |
|
Isoniazid
|
CYP2E1 induction; increased NAPQI (toxic metabolite) formation | Increased hepatotoxicity risk | Monitor LFTs; use lowest effective paracetamol dose; counsel patient |
|
Rifampicin
|
CYP enzyme induction; increased NAPQI formation | Increased hepatotoxicity risk; possible reduced analgesic efficacy | Monitor LFTs; limit paracetamol use during TB treatment if possible |
Moderate drug interactions
| Interacting Drug | Effect | Management |
|---|---|---|
|
Phenytoin, Carbamazepine, Phenobarbital
|
CYP enzyme induction; increased NAPQI formation; possible reduced paracetamol efficacy | Use with caution for prolonged periods; monitor for hepatotoxicity |
|
Lamotrigine
|
Paracetamol may increase lamotrigine clearance (via UGT induction) | Monitor lamotrigine levels/efficacy if concurrent chronic use |
|
Metoclopramide, Domperidone
|
Increased rate of paracetamol absorption | Generally beneficial for faster analgesia; no dose adjustment needed |
|
Cholestyramine
|
Reduced paracetamol absorption | Separate administration by at least 1 hour |
|
Chloramphenicol (IV)
|
Reduced chloramphenicol clearance | Monitor chloramphenicol levels; clinical relevance uncertain |
|
Zidovudine (AZT)
|
Possible increased risk of neutropenia | Monitor blood counts with prolonged concurrent use |
Common Adverse effects
- Nausea (uncommon at therapeutic doses)
- Rash, pruritus (uncommon)
- Hypersensitivity reactions (uncommon)
Note: Paracetamol has an excellent safety profile at therapeutic doses. Most adverse effects occur with overdose or prolonged high-dose use.
Serious Adverse effects
| Adverse Effect | Clinical Action |
|---|---|
|
Acute Hepatotoxicity / Fulminant Hepatic Failure (with overdose >150 mg/kg or >7.5 g in adults, or chronic supratherapeutic dosing)
|
Discontinue immediately; check serum paracetamol level at 4 hours post-ingestion; initiate N-acetylcysteine (NAC) per Rumack-Matthew nomogram; hepatology/poison centre consultation; may require liver transplant in severe cases |
|
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (rare)
|
Discontinue permanently; dermatology consultation; supportive care; hospitalisation |
|
Anaphylaxis (rare)
|
Discontinue permanently; emergency management |
|
Agranulocytosis / Thrombocytopenia (very rare)
|
Discontinue; haematology consultation |
|
Acute Generalised Exanthematous Pustulosis (AGEP) (very rare)
|
Discontinue; dermatology consultation |
Paracetamol Overdose Management:
- Toxic dose: >150 mg/kg or >7.5 g (whichever is lower) in adults; >200 mg/kg in children
- Obtain serum paracetamol level at 4 hours post-ingestion (or as soon as possible if presentation delayed)
- N-acetylcysteine (NAC) is life-saving; initiate based on Rumack-Matthew nomogram or if toxic dose ingested (even before levels available if >8 hours since ingestion)
- Contact National Poison Information Centre (AIIMS) for guidance: 1800-116-117
Monitoring requirements
| Timing | Parameters |
|---|---|
|
Baseline
|
Not required for short-term use in healthy patients; LFTs if hepatic risk factors present or planned prolonged use |
|
Short-term use (<5 days)
|
No routine monitoring required |
|
Prolonged/Chronic use (>5–7 days)
|
LFTs (baseline and periodic); assess total paracetamol intake from all sources |
|
High-risk patients (alcoholism, malnutrition, hepatic disease)
|
LFTs before initiation and periodically during use |
|
Suspected overdose
|
Serum paracetamol level at 4 hours post-ingestion; LFTs (AST, ALT, bilirubin); PT/INR; renal function; blood glucose |
Brands in India
Oral Tablets:
- Crocin™ (GSK) — 500 mg, 650 mg
- Calpol™ (GSK) — 500 mg
- Dolo™ (Micro Labs) — 650 mg
- Pacimol™ (Ipca) — 500 mg, 650 mg
- Pyrigesic™ (East India) — 500 mg
- Metacin™ (Aristo) — 500 mg
- Paracip™ (Cipla) — 500 mg, 650 mg
Paediatric Formulations (Syrups/Drops):
- Calpol™ Paediatric Suspension — 120 mg/5 mL, 250 mg/5 mL
- Crocin™ Drops — 100 mg/mL
- Pacimol™ Drops — 100 mg/mL
- T-98™ Drops — 100 mg/mL
- Febrinil™ — 125 mg/5 mL
Intravenous:
- Perfalgan™ (Bristol-Myers Squibb) — 10 mg/mL (100 mL vial)
- Aceparon™ — 10 mg/mL
- Paracip IV™ (Cipla) — 10 mg/mL
Suppositories:
- Crocin™ Suppository — 125 mg, 250 mg
- Febrinil™ Suppository — 80 mg, 170 mg
Fixed-Dose Combinations (Examples):
- Paracetamol + Ibuprofen (Combiflam™)
- Paracetamol + Tramadol (Ultracet™)
- Paracetamol + Caffeine + Various analgesics (multiple OTC brands)
⚠️ Important: Always calculate total paracetamol intake from all sources including FDCs.
Price range (INR)
| 500 mg tablet | ₹0.20–₹0.60 per tablet | NLEM listed; NPPA price controlled |
|---|---|---|
| 650 mg tablet | ₹0.50–₹2.00 per tablet | — |
| 1000 mg tablet | ₹2.00–₹4.00 per tablet | — |
| Syrup (60 mL) | ₹15–₹45 | — |
| Paediatric drops (15 mL) | ₹20–₹50 | — |
| IV infusion (100 mL = 1000 mg) | ₹80–₹220 per vial | Significant cost,reserve for appropriate indications |
| Suppositories | ₹8–₹15 per suppository | — |
Regulatory: Listed under NLEM 2022 (500 mg tablet, paediatric oral liquid); NPPA price controlled for scheduled strengths
Clinical pearls
- Calculate total daily dose from ALL sources — Paracetamol is present in numerous FDCs (cold/flu preparations, analgesic combinations); inadvertent overdose is common; always ask about OTC medication use
- Preferred analgesic/antipyretic in special populations — First-line in pregnancy, breastfeeding, children <6 months, elderly with GI/CV/renal risk, dengue fever (avoid NSAIDs), and patients on anticoagulants
- IV paracetamol is expensive — Reserve for patients genuinely unable to take oral medications; switch to oral route as soon as feasible; efficacy is similar (IV has faster onset)
- Hepatotoxicity risk in "at-risk" patients — Chronic alcoholics, malnourished patients, and those on enzyme inducers (isoniazid, rifampicin, phenytoin) may develop hepatotoxicity at therapeutic doses; limit to 2000–3000 mg/day in these patients
- Early NAC is life-saving in overdose — Do not delay NAC therapy waiting for paracetamol levels if toxic dose ingested >8 hours ago; the 4-hour level guides but should not delay treatment in late presenters
- Weight-based dosing in children is essential — Use calibrated measuring devices for liquid formulations; avoid household spoons; ensure caregiver understanding
Version
RxIndia v1.1 — 11 Apr 2025
Reference
- CDSCO Product Information
- Indian Pharmacopoeia (IP)
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- AIIMS Drug Formulary
- IAP Guidelines — Fever Management in Children
- MoHFW Paediatric Dosing Guidelines
- ICMR Guidelines on Rational Use of Analgesics
- National Poison Information Centre (AIIMS) — Paracetamol Toxicity Management Protocol
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- Harrison's Principles of Internal Medicine
- Perfalgan™ / IV Paracetamol Prescribing Information (India)
- RCTs on Paracetamol for PDA closure (Hammerman et al., Ohlsson et al.) — off-label evidence
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.